Pharmacovigilance Market Insights Highlight Segment Expansion And Market Leadership

The pharmacovigilance sector has seen swift expansion in recent times, driven by multiple factors influencing drug safety and monitoring. As the industry evolves, new developments and increasing complexities in pharmaceutical oversight are setting the stage for continued growth through 2030. Let's explore the current market size, key growth drivers, prominent players, emerging trends, and segment breakdowns shaping this important field.

Pharmacovigilance Market Size and Growth Prospects Through 2030
The pharmacovigilance market has experienced notable growth and is expected to continue this momentum. The market value is projected to increase from $9.64 billion in 2025 to $10.86 billion in 2026, growing at a compound annual growth rate (CAGR) of 12.7%. This previous surge is mainly due to heightened reporting of adverse drug reactions, expanded pharmaceutical approvals worldwide, a rise in clinical trial activities, the implementation of international drug safety regulations, and increased use of medications for chronic illnesses.
Looking ahead, the market is forecasted to expand rapidly, reaching $17.41 billion by 2030 with a CAGR of 12.5%. This growth will be driven by factors such as broader adoption of real-world data, a spike in approvals for biologics and biosimilars, the increasing complexity of combination therapies, growth of pharmacovigilance in emerging markets, and intensified focus on patient safety outcomes. Key trends expected to influence this expansion include more extensive post-marketing surveillance, growing reliance on real-world evidence for safety assessments, heightened regulatory oversight, increased outsourcing of pharmacovigilance functions, and integration of multi-source safety data platforms.

Download a free sample of the pharmacovigilance market report:
https://thebusinessresearchcompany.com/sample_request?id=43491693&type=smp&name=Pharmacovigilance%20Market%20Report%202026&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Oct_PR

Factors Contributing to the Expansion of the Pharmacovigilance Market
A significant element behind market growth is the expanding use of real-world data, which enables more comprehensive safety monitoring beyond traditional clinical trials. This approach supports better detection of adverse events and informs decision-making for patient care and drug regulation. Furthermore, the surge in approvals for biologics and biosimilars presents additional challenges requiring advanced pharmacovigilance practices due to their complex nature and safety profiles.
The market also benefits from the growing complexity of combination therapies, which demand careful monitoring to manage potential interactions and adverse effects. Additionally, emerging economies are strengthening their pharmacovigilance frameworks, adding new growth regions. The increasing emphasis on patient safety outcomes ensures that stakeholders prioritize effective monitoring and risk management throughout the product lifecycle.

Key Players Leading the Pharmacovigilance Industry
Several influential companies play a major role in shaping the pharmacovigilance landscape, including IQVIA, Cognizant, ICON Plc, accenture* plc, PAREXEL International Corporation, United BioSource LLC, ArisGlobal, Quanticate, Wipro Limited, Linical Americas, Novotech CRO, EXTEDO, Arriello, PrimeVigilance, Axios International, C3i Solutions, Secure AI Labs, OmniSol dot Tech, Prevnos Inc., Lifescient Inc, QuintilesIMS, Labcorp Drug Development, Pharmaceutical Product Development Inc., PRA Health Sciences, Synowledge LLC, RAPAhub, illuminate health, Invenio Medical, ClinChoice Inc., Novasyte, Fortrea Holdings Inc., Syneos Health Clinical, and Telerx Marketing Inc.
A notable recent development occurred in January 2023, when AmerisourceBergen, a US-based pharmaceutical wholesale company, acquired Pharma Lex in a deal whose financial details were not disclosed. This acquisition is anticipated to enhance AmerisourceBergen's service capabilities, allowing it to better support pharmaceutical and biotech firms through comprehensive pharmacovigilance solutions. Pharma Lex's team, based in Germany, offers end-to-end services covering pharmacovigilance systems, operational management, and benefit-risk assessment.

View the full pharmacovigilance market report:
https://www.thebusinessresearchcompany.com/report/pharmacovigilance-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Oct_PR

Emerging Trends Boosting Pharmacovigilance Market Expansion
Artificial intelligence (AI) is becoming a vital tool for many pharmacovigilance companies seeking to improve operational efficiency and accuracy. By leveraging AI, pharmaceutical organizations can enhance data handling, accelerate drug development processes, reduce costs, and ultimately improve patient safety outcomes.
For example, in August 2024, the Government of India launched the Adverse Drug Reaction Monitoring System (ADRMS) software, unveiled by the Minister of Health & Family Welfare and Minister of Chemicals and Fertilizers. This platform simplifies the reporting and analysis of adverse events related to medications and medical devices, benefiting both healthcare providers and consumers. The ADRMS initiative strengthens India's pharmacovigilance infrastructure by enabling more thorough safety data collection and better regulatory compliance, positioning the country as a key player in the global pharmaceutical arena.

Breakdown of Key Segments in the Global Pharmacovigilance Market
The pharmacovigilance market is segmented across various categories to provide a detailed view of its structure:
1) By Type: spontaneous reporting, intensified adverse drug reaction (ADR) reporting, targeted spontaneous reporting, cohort event monitoring, and electronic health record (EHR) mining.
2) By Service Provider: in-house services versus contract outsourcing.
3) By Process Flow: includes case data management, signal detection, and risk management systems.
4) By Clinical Trial Phase: covering preclinical stages through to Phase IV trials.
5) By End User: hospitals, pharmaceutical companies, and other relevant users.
Further subsegments include specifics such as individual case safety reports (ICSRs), voluntary and healthcare professional reporting under spontaneous reporting; active surveillance and enhanced monitoring in intensified ADR reporting; condition-specific focus within targeted spontaneous reporting; prospective and retrospective cohort studies in cohort event monitoring; and EHR data extraction and integration for safety signal detection.

Our 2026 reports feature deeper market intelligence with market attractiveness scoring and analysis, total addressable market (TAM) analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technologies and future trend analysis, and updated graphics and tables.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.